Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial
暂无分享,去创建一个
J. Victorino | F. Thomé | L. Röhsig | E. O. Garcés | Estela Dornelles | Marcelo Louzada | Jonhatas Stifft | Felipe de Holanda | F. V. Veronese
[1] R. Mehta,et al. Renal replacement therapy for acute renal failure. , 2009, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.
[2] N. Clark,et al. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency. , 2008, Thrombosis research.
[3] E. Will,et al. Anticoagulation with low molecular weight heparin (Fragmin) during continuous hemodialysis in the intensive care unit. , 2008, Artificial organs.
[4] H. Ulmer,et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study , 2007, Intensive Care Medicine.
[5] S. Opal,et al. Coagulation abnormalities in critically ill patients , 2006, Critical care.
[6] F. Dentali,et al. Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency , 2006, Annals of Internal Medicine.
[7] C. Ronco,et al. Practice patterns in the management of acute renal failure in the critically ill patient: an international survey. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[8] J. Wester,et al. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? , 2006, Intensive Care Medicine.
[9] P. Prandoni,et al. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. , 2005, Blood.
[10] C. Sucker,et al. The heparins: all a nephrologist should know. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[11] R. Bellomo,et al. Acute renal failure in critically ill patients: a multinational, multicenter study. , 2005, JAMA.
[12] Jeremy J Lee,et al. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. , 2004, American heart journal.
[13] H. Bueno,et al. Fatal retroperitoneal haemorrhage associated with enoxaparin and impaired renal function. , 2004, International journal of cardiology.
[14] A. Hartmann,et al. Low molecular weight heparins as thromboprophylaxis in patients undergoing hemodialysis/hemofiltration or continuous renal replacement therapies. , 2004, European journal of medical research.
[15] D. O'donoghue,et al. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[16] P. Murray,et al. Pharmacologic issues in the critically ill. , 2003, Clinics in chest medicine.
[17] J. Kelton,et al. Frequency of Heparin‐Induced Thrombocytopenia in Critical Care Patients , 2003, Pharmacotherapy.
[18] L. Moist,et al. Acute renal failure in the ICU: assessing the utility of continuous renal replacement. , 2003, Journal of critical care.
[19] A. Davenport,et al. The Acute Dialysis Quality Initiative--part VI: access and anticoagulation in CRRT. , 2002, Advances in renal replacement therapy.
[20] B. Boutouyrie,et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. , 2002, Thrombosis research.
[21] P. Monagle,et al. Mechanisms responsible for the failure of protamine to inactivate low‐molecular‐weight heparin , 2002, British journal of haematology.
[22] M. Schetz. Anticoagulation for continuous renal replacement therapy , 2001, Current opinion in anaesthesiology.
[23] P. Gaussem,et al. [Monitoring of tinzaparin in a ten day treatment dose in elderly patients]. , 2001, La Revue de medecine interne.
[24] É. Pautas,et al. Surveillance d'un traitement par la tinzaparine à dose curative pendant dix jours chez le sujet âgéMonitoring of tinzaparin treatment at treatment dose of 10 days in elderly patients. , 2001 .
[25] S. Opal,et al. Therapeutic rationale for antithrombin III in sepsis , 2000, Critical care medicine.
[26] J. F. Barnes,et al. Enoxaparin and Bleeding Complications: A Review in Patients with and without Renal Insufficiency , 2000, Pharmacotherapy.
[27] H. O. Oudemans-van Straaten,et al. Nadroparin versus dalteparin anticoagulation in high‐volume, continuous venovenous hemofiltration: A double‐blind, randomized, crossover study , 2000, Critical care medicine.
[28] J. Westhuyzen,et al. Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[29] J. Santamaria,et al. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. , 1999, Critical care medicine.
[30] A. Kaye,et al. Effect of anticoagulation on blood membrane interactions during hemodialysis. , 1999, Kidney international.
[31] A. Hartmann,et al. A single dose of dalteparin effectively prevents clotting during haemodialysis. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[32] S. Goldhaber,et al. Clinical uses of low-molecular-weight heparins. , 1999, Chest.
[33] T. Ortel,et al. Heparin-induced thrombocytopenia. , 1998, Annual review of medicine.
[34] G. Gallioli,et al. Antithrombin III (ATILL) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study , 1998, Intensive Care Medicine.
[35] J. Hirsh,et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. , 1995, The New England journal of medicine.
[36] J. Harenberg,et al. Nephrology Dialysis Transplantation Monitoring of Heparins in Haemodialysis Using an Anti-factor-xa-specific Whole-blood Clotting Assay , 2022 .
[37] R. Mehta,et al. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. , 1990, Kidney international.
[38] R. Miller,et al. Renal replacement therapy in the ICU: the role of continuous arteriovenous haemodialysis. , 1990, British journal of hospital medicine.
[39] G. Screaton,et al. Heparin clearance during continuous veno-venous haemofiltration , 2005, Intensive Care Medicine.
[40] É. Pautas,et al. Safety Profile of Tinzaparin Administered Once Daily at a Standard Curative Dose in Two Hundred Very Elderly Patients , 2002, Drug safety.
[41] E. Ohman,et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. , 2001, Chest.
[42] G. Gallioli,et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. , 1998, Intensive care medicine.
[43] G. R. Wise. Clinical uses for low-molecular-weight heparins. , 1996, The Western journal of medicine.
[44] O. Toupance,et al. Guidelines to the use of enoxaparin in slow continuous hemodialysis. , 1991, Contributions to nephrology.